↓ Skip to main content
Farsalinos
Farsalinos
English ΕΛΛΗΝΙΚΑ
  1. NEWS/

News-Week, August 20–26, 2026

·573 words·3 mins·
K. Farsalinos, MD, MPH, PhD | Science & Public Health
Author
K. Farsalinos, MD, MPH, PhD | Science & Public Health
Table of Contents

Covering news published August 20–26, 2026

Regulators, Researchers Issue Dueling Signals on Safer Nicotine Products
#

U.S. regulators kept expanding the market for lower-risk nicotine products in the final week of August 2026, even as major pediatric and public health bodies published sobering evidence on vaping’s effects on young people — and a landmark evidence review reaffirmed vaping’s edge as a quit-smoking tool for adults.

FDA authorizes another batch of nicotine pouches
#

On August 21, the FDA authorized 11 new nicotine pouch products for marketing through its premarket tobacco product application (PMTA) pathway, bringing the total number of FDA-authorized nicotine pouches to 43. The pouches, in mint, citrus, and other cooling flavors, were reviewed under the agency’s nicotine pouch “pilot program,” created to speed up scientific review. The FDA said its assessment found the products contain lower levels of most harmful constituents than other smokeless tobacco products, and that switching completely to authorized pouches “may reduce exposure to many harmful chemicals” for adult smokers and smokeless tobacco users.

Industry momentum builds around pouches globally
#

A day earlier, a Reuters analysis described how nicotine pouches have become a central growth strategy for major tobacco companies worldwide, as manufacturers try to persuade smokers outside Scandinavia and the U.S. — regions without a strong oral-nicotine tradition — to adopt the category. The piece noted rapid volume growth across Asia, the Middle East, and Africa, alongside continued regulatory uncertainty as governments scrutinize youth marketing and uptake.

Pediatricians warn of vaping’s effects on children
#

Also on August 20, the UK’s Royal College of Paediatrics and Child Health (RCPCH) published one of the most comprehensive reviews to date on vaping’s impact on children, in the journal Archives of Disease in Childhood. Analyzing more than 14,000 published articles and synthesizing 81 studies, the review found consistent evidence linking youth vaping with worse respiratory health — including coughing, wheezing, and asthma exacerbations — plus signals around poorer mental health and higher rates of subsequent cigarette smoking. Follow-up coverage on August 21 noted paediatricians are calling on the UK government to further restrict the vape flavors available to minors, arguing the incoming Tobacco and Vapes Act shouldn’t be treated as a “one-and-done” fix.

Cochrane review: vapes outperform nicotine replacement therapy
#

Capping the week, the Cochrane Collaboration published an updated living systematic review on August 26 concluding nicotine e-cigarettes remain more effective for smoking cessation than nicotine replacement therapy (patches, gum, lozenges) or behavioral support alone. Drawing on 80 randomized controlled trials involving nearly 30,000 participants, the review found high-certainty evidence that vaping produces roughly four more successful quitters per 100 smokers than nicotine replacement therapy, and about two more than non-nicotine vaping devices. Reviewers found no clear evidence of increased serious adverse events tied to vaping, though they cautioned long-term safety data remain limited.

Sources
#